HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358

Benzinga Newsdesk www.benzinga.com Positive 83.3%

Neg 0% Neu 0% Pos 83.3%

HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $289 to $358.